Real-Life Value of the Odysight® Application in At-Home Screening for Exudative Recurrence of Macular Edema

Gauthier Kielwasser, Laurent Kodjikian, Corinne Dot, Carole Burillon, Philippe Denis, Thibaud Mathis, Gauthier Kielwasser, Laurent Kodjikian, Corinne Dot, Carole Burillon, Philippe Denis, Thibaud Mathis

Abstract

Background: The aim of this study was to describe the value of the Odysight® application in addition to a classical follow-up regimen in the detection of exudative recurrences in patients with macular edema. Methods: We conducted an observational, multicenter, retrospective study. The Odysight® application includes a visual acuity (VA) test that can lead to alerts in case of a drop of >5 VA letters on two successive tests. The efficacy of the alerts in detecting exudative recurrence was studied. Results: A total of 149 eyes of 123 patients were included. The sensitivity of alerts for the detection of recurrence was 30.8% (95% CI [17.6; 44.0]) and its specificity was 83.7% (95% CI [73.2; 94.3]. A better baseline VA was found to be significantly associated with a better retention of the application (OR = 0.05, 95% CI [0.002; 0.62]; p = 0.045). Of the 12/39 alerts that detected a recurrence, eight (20.5% of all alerts) resulted in the scheduling or advancement of an intravitreal injection. Conclusions: In the present study, the sensitivity and positive predictive value of the Odysight® application seems low but its use in addition to the usual follow-up of the patient can detect, in certain cases, an early recurrence and thus allow an anticipated readjustment of the treatment.

Keywords: Odysight®; age-related macular degeneration; intravitreal injection; macular edema; telemedicine.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Images from the application: (a) VA test; (b) message when an alert occurs; (c) Amsler grid.
Figure 2
Figure 2
Flow chart.
Figure 3
Figure 3
Estimated retention rate using the Kaplan–Meier method. Yellow line: probability of retention. Grey zone, 95% confidence interval, dotted line: median duration of use.

References

    1. Bloch S.B., Larsen M., Munch I.C. Incidence of Legal Blindness from Age-Related Macular Degeneration in Denmark: Year 2000 to 2010. Am. J. Ophthalmol. 2012;153:209–213.e2. doi: 10.1016/j.ajo.2011.10.016.
    1. Mehta H., Kim L.N., Mathis T., Zalmay P., Ghanchi F., Amoaku W.M., Kodjikian L. Trends in Real-World Neovascular AMD Treatment Outcomes in the UK. Clin. Ophthalmol. 2020;14:3331–3342. doi: 10.2147/OPTH.S275977.
    1. Kodjikian L., Bellocq D., Mathis T. Pharmacological Management of Diabetic Macular Edema in Real-Life Observational Studies. BioMed Res. Int. 2018;28:8289253. doi: 10.1155/2018/8289253.
    1. Mehta H., Tufail A., Daien V., Lee A.Y., Nguyen V., Ozturk M., Barthelmes D., Gillies M.C. Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Prog. Retin. Eye Res. 2018;65:127–146. doi: 10.1016/j.preteyeres.2017.12.002.
    1. Lai T.T., Chen T.C., Yang C.H., Yang C.M., Ho T.C., Hsieh Y.T. Treat-and-Extend vs. Pro Re Nata Regimen of Ranibizumab for Diabetic Macular Edema—A Two-Year Matched Comparative Study. Front. Med. 2022;8:781421. doi: 10.3389/fmed.2021.781421.
    1. Faes L., Bodmer N.S., Bachmann L.M., Thiel M.A., Schmid M.K. Diagnostic accuracy of the Amsler grid and the preferential hyperacuity perimetry in the screening of patients with age-related macular degeneration: Systematic review and meta-analysis. Eye. 2014;28:788–796. doi: 10.1038/eye.2014.104.
    1. Zaidi F.H., Cheong-Leen R., Gair E.J., Weir R., Sharkawi E., Lee N., Gregory-Evans K. The Amsler chart is of doubtful value in retinal screening for early laser therapy of subretinal membranes. The West London Survey. Eye. 2004;18:503–508. doi: 10.1038/sj.eye.6700708.
    1. Chamard C., Lacombe S., Navarre S., Rohart C., Daures J.P., Allieu S. Is current age related macular degeneration self-monitoring a good tool for detecting exudative recurrence? J. Fr. Ophtalmol. 2019;42:1049–1055. doi: 10.1016/j.jfo.2019.02.017.
    1. Chew E.Y., Clemons T.E., Bressler S.B., Elman M.J., Danis R.P., Domalpally A., Heier J.S., Kim J.E., Garfinkel R.A. Randomized trial of the ForeseeHome monitoring device for early detection of neovascular age-related macular degeneration. The HOme Monitoring of the Eye (HOME) study design—HOME Study report number 1. Contemp. Clin. Trials. 2014;37:294–300. doi: 10.1016/j.cct.2014.02.003.
    1. Kaiser P.K., Wang Y.Z., He Y.G., Weisberger A., Wolf S., Smith C.H. Feasibility of a novel remote daily monitoring system for age-related macular degeneration using mobile handheld devices: Results of a Pilot Study. Retina. 2013;33:1863–1870. doi: 10.1097/IAE.0b013e3182899258.
    1. Schmid M.K., Thiel M.A., Lienhard K., Schlingemann R.O., Faes L., Bachmann L.M. Reliability and diagnostic performance of a novel mobile app for hyperacuity self-monitoring in patients with age-related macular degeneration. Eye. 2019;33:1584–1589. doi: 10.1038/s41433-019-0455-6.
    1. Brucker J., Bhatia V., Sahel J.-A., Girmens J.-F., Mohand-Saïd S. Odysight: A Mobile Medical Application Designed for Remote Monitoring—A Prospective Study Comparison with Standard Clinical Eye Tests. Ophthalmol. Ther. 2019;8:461–476. doi: 10.1007/s40123-019-0203-9.
    1. Guigou S., Michel T., Mérité P.-Y., Coupier L., Meyer F. Home vision monitoring in patients with maculopathy: Real-life study of the OdySight application. J. Fr. Ophtalmol. 2021;44:873–881. doi: 10.1016/j.jfo.2020.09.034.
    1. Bellocq D., Akesbi J., Matonti F., Vartin C., Despreaux R., Comet A., Voirin N., Denis P., Mathis T., Kodjikian L. The Pattern of Recurrence in Diabetic Macular Edema Treated by Dexamethasone Implant: The PREDIAMEX Study. Ophthalmol. Retina. 2018;2:567–573. doi: 10.1016/j.oret.2017.10.016.
    1. Wang V.Y., Kuo B.L., Chen A.X., Wang K., Greenlee T.E., Conti T.F., Singh R.P. Fluctuations in macular thickness in patients with diabetic macular oedema treated with anti-vascular endothelial growth factor agents. Eye. 2021;36:1461–1467. doi: 10.1038/s41433-021-01672-1.
    1. Evans R.N., Reeves B.C., Maguire M.G., Martin D.F., Muldrew A., Peto T., Rogers C., Chakravarthy U. Associations of Variation in Retinal Thickness with Visual Acuity and Anatomic Outcomes in Eyes with Neovascular Age-Related Macular Degeneration Lesions Treated with Anti–Vascular Endothelial Growth Factor Agents. JAMA Ophthalmol. 2020;138:1043. doi: 10.1001/jamaophthalmol.2020.3001.
    1. Nicolas C., Debellemanière G., Boissier F., Girard C., Schwartz C., Delbosc B., Saleh M. Reproductibilité des mesures de l’acuité visuelle par échelle ETDRS en pratique quotidienne. J. Fr. Ophtalmol. 2016;39:700–705. doi: 10.1016/j.jfo.2016.03.007.
    1. Siderov J., Tiu A.L. Variability of measurements of visual acuity in a large eye clinic: Variability of measurements of visual acuity in a large eye clinic. Acta Ophthalmol. Scand. 1999;77:673–676. doi: 10.1034/j.1600-0420.1999.770613.x.
    1. Rosser D.A., Cousens S.N., Murdoch I.E., Fitzke F.W., Laidlaw D.A.H. How Sensitive to Clinical Change are ETDRS logMAR Visual Acuity Measurements? Investig. Opthalmol. Vis. Sci. 2003;44:3278. doi: 10.1167/iovs.02-1100.
    1. Keane P.A., De Salvo G., Sim D.A., Goverdhan S., Agrawal R., Tufail A. Strategies for improving early detection and diagnosis of neovascular age-related macular degeneration. Clin. Ophthalmol. 2015;9:353–366. doi: 10.2147/OPTH.S59012.
    1. Teo K.Y.C., Bachmann L.M., Sim D., Lee S.Y., Tan A., Wong T.Y., Cheung C.M.G., Tan G.S.W. Patterns and Characteristics of a Clinical Implementation of a Self-Monitoring Program for Retina Diseases during the COVID-19 Pandemic. Ophthalmol. Retina. 2021;5:1245–1253. doi: 10.1016/j.oret.2021.02.005.
    1. Islam M., Sansome S., Das R., Lukic M., Teo K.Y.C., Tan G., Balaskas K., Thomas P.B.M., Bachmann L.M., Schimel A.M., et al. Smartphone-based remote monitoring of vision in macular disease enables early detection of worsening pathology and need for intravitreal therapy. BMJ Health Care Inform. 2021;28:e100310. doi: 10.1136/bmjhci-2020-100310.
    1. Faes L., Islam M., Bachmann L.M., Lienhard K.R., Schmid M.K., Sim D.A. False alarms and the positive predictive value of smartphone-based hyperacuity home monitoring for the progression of macular disease: A prospective cohort study. Eye. 2021;35:3035–3040. doi: 10.1038/s41433-020-01356-2.
    1. Gross N., Bachmann L.M., Islam M., Faes L., Schmid M.K., Thiel M., Schimel A., Sim D. Visual outcomes and treatment adherence of patients with macular pathology using a mobile hyperacuity home-monitoring app: A matched-pair analysis. BMJ Open. 2021;11:e056940. doi: 10.1136/bmjopen-2021-056940.
    1. Ward E., Wickens R.A., O’Connell A., Culliford L.A., Rogers C.A., Gidman E.A., Peto T., Knox P.C., Burton B.J.L., Lotery A.J., et al. Monitoring for neovascular age-related macular degeneration (AMD) reactivation at home: The MONARCH study. Eye. 2021;35:592–600. doi: 10.1038/s41433-020-0910-4.
    1. Nikam A., Lefumat H., Grondin E., Bhatia V. OdySight: Real-World Data Analysis of a Mobile Medical Application for Ophthalmology. J. Ophthalmol. Sci. 2020;2:6–12.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe